Xxosixxlarxxnewxx Lixxted Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Xxosixxlarxxnewxx Lixxted Pharmaceutical Import Records from India — 2 Products, $1.9M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Xxosixxlarxxnewxx Lixxted — Pharmaceutical Importer Profile (2026) | 2 Products, $1.9M Trade | TransData Nexus

Xxosixxlarxxnewxx Lixxted

Pharmaceutical Importer · United States · Ayurvedic & Herbal Products Focus · $1.9M Total Trade · DGFT Verified

Xxosixxlarxxnewxx Lixxted is a pharmaceutical importer based in United States with a total trade value of $1.9M across 2 products in 2 therapeutic categories. Based on 37 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Xxosixxlarxxnewxx Lixxted sources from 1 verified Indian supplier, with Biocon Biologics India Limited accounting for 100.0% of imports.

Xxosixxlarxxnewxx Lixxted — Import Portfolio & Supplier Network

Xxosixxlarxxnewxx Lixxted import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Xxosixxlarxxnewxx Lixxted?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Biocon Biologics India Limited	$1.7M	38	100.0%

Xxosixxlarxxnewxx Lixxted sources from 1 verified Indian supplier across 14 distinct formulations. The sourcing is highly concentrated — Biocon Biologics India Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Fulphila pegfilgrastim-jmdb	$600.0K	12
Fulphila (pegfilgrastim-jmdb)	$300.0K	6
Ogivri 420 trastuzumab	$150.0K	3
Fulphila 6MG/0.6ML	$118.1K	4
Fulphila pegfilgrastim-	$100.0K	2
Fulphila (pegfilgrastim-	$100.0K	2
Fulphila 6MG - mylan	$96.5K	2
Ogivri tm trastuzumab	$50.0K	1
Abevmy 25 MG/ML	$50.0K	1
Ogivri 150 trastuzumab	$50.0K	1
Fulphila pegfilgrastim-	$50.0K	1
Ogivri 150 trastuzumab for	$50.0K	1
Trastuzumab for	$8.3K	1
Abevmy # 400 bevacizumab	$7.2K	1

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Ras	Ayurvedic & Herbal Products	$1.5M	30	0.5%	4
2	Trastuzumab	Advanced Oncology	$350.0K	7	0.5%	7

Xxosixxlarxxnewxx Lixxted imports 2 pharmaceutical products across 2 categories into United States totaling $1.9M.

Xxosixxlarxxnewxx Lixxted — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Xxosixxlarxxnewxx Lixxted is a pharmaceutical importer and buyer based in the United States, specializing in the acquisition of finished pharmaceutical formulations from international suppliers. The company operates as a key player in the U.S. pharmaceutical distribution network, focusing on sourcing and importing specific therapeutic products to meet domestic market demands. While detailed information about its headquarters and parent company is not publicly available, Xxosixxlarxxnewxx Lixxted's role is pivotal in facilitating the availability of specialized pharmaceutical products within the U.S. market.

2Distribution Network

Specific details regarding Xxosixxlarxxnewxx Lixxted's warehouse locations and logistics capabilities are not publicly disclosed. However, the company's operations suggest a distribution network that effectively manages the importation and distribution of pharmaceutical products across the United States. Given the nature of its imports, it is likely that Xxosixxlarxxnewxx Lixxted collaborates with established logistics providers to ensure timely and compliant delivery of products to various regions within the U.S.

3Industry Role

Xxosixxlarxxnewxx Lixxted functions primarily as a pharmaceutical importer and buyer within the U.S. supply chain. By sourcing finished pharmaceutical formulations from international suppliers, the company plays a crucial role in enhancing the diversity and availability of therapeutic options in the U.S. market. This position allows Xxosixxlarxxnewxx Lixxted to address specific market needs and contribute to the overall efficiency of pharmaceutical distribution in the United States.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Xxosixxlarxxnewxx Lixxted

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Xxosixxlarxxnewxx Lixxted's sourcing strategy exhibits a high degree of concentration, with a total import value of $1.9 million USD from India across 37 shipments, all sourced from a single supplier: Biocon Biologics India Limited. This exclusive sourcing arrangement indicates a strategic partnership, potentially offering benefits such as favorable pricing, consistent product quality, and reliable supply chain management. However, this single-source dependency also introduces risks, including vulnerability to supply disruptions or changes in the supplier's operational status. The absence of alternative suppliers may limit Xxosixxlarxxnewxx Lixxted's ability to mitigate such risks effectively.

2Supply Chain Resilience

The resilience of Xxosixxlarxxnewxx Lixxted's supply chain is closely tied to its exclusive relationship with Biocon Biologics India Limited. While this partnership may ensure product consistency and quality, the lack of backup suppliers could pose challenges in the event of supply chain disruptions. The company's focus on a limited number of formulations—14 unique formulations across two therapeutic categories—suggests a specialized product portfolio. This specialization may limit the flexibility of the supply chain, making it more susceptible to fluctuations in demand or production issues. Additionally, the reliance on a single supplier necessitates a thorough assessment of Biocon Biologics' manufacturing capabilities, regulatory compliance, and financial stability to ensure uninterrupted supply.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation and marketing of pharmaceutical products. The FDA enforces regulations that ensure the safety, efficacy, and quality of drugs entering the U.S. market. Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act (FDCA), which outlines the standards for drug approval and importation. The Drug Enforcement Administration (DEA) also plays a role in regulating controlled substances. For Indian generics to enter the U.S. market, they must undergo the FDA's Abbreviated New Drug Application (ANDA) process, demonstrating bioequivalence to the reference listed drug. This pathway ensures that generic drugs meet the same standards as their brand-name counterparts, facilitating their approval for marketing in the United States.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in the United States are stringent. Manufacturers and importers must register with the FDA and comply with Current Good Manufacturing Practice (cGMP) regulations. The FDA recognizes various international cGMP certifications, including those from the European Union (EU GMP), World Health Organization (WHO GMP), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). These certifications are crucial for foreign manufacturers seeking to export to the U.S., as they demonstrate adherence to internationally accepted quality standards. Additionally, wholesale distributors must obtain appropriate state licenses to operate legally within the U.S. market.

Xxosixxlarxxnewxx Lixxted — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Xxosixxlarxxnewxx Lixxted's focus on Ayurvedic & Herbal Products and Advanced Oncology indicates a strategic alignment with therapeutic areas experiencing significant demand in the U.S. market. The substantial import value of Ras ($1.5 million) and Trastuzumab ($350,000) suggests a targeted approach to sourcing products that address prevalent health conditions. The company's portfolio concentration, with the top five products accounting for 100% of imports, reflects a strategy focused on high-demand, specialized products.

2Sourcing Profile

Xxosixxlarxxnewxx Lixxted's sourcing strategy emphasizes the importation of generic drugs, particularly in the Ayurvedic & Herbal and Advanced Oncology categories. The company's preference for finished pharmaceutical formulations aligns with the need for ready-to-market products that meet U.S. regulatory standards. India's established pharmaceutical manufacturing capabilities and adherence to international quality standards make it a suitable partner for Xxosixxlarxxnewxx Lixxted's procurement needs.

3Market Positioning

Based on its product mix, Xxosixxlarxxnewxx Lixxted serves a segment of the U.S. market that includes retail pharmacies, hospitals, and potentially government tenders. The focus on specialized therapeutic areas suggests a role in supplying niche products to healthcare providers and patients seeking alternative or complementary treatments. The company's strategic sourcing and importation practices position it to meet specific market demands effectively.

Seller's Guide — How to Become a Supplier to Xxosixxlarxxnewxx Lixxted

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Xxosixxlarxxnewxx Lixxted, particularly if they can offer products that align with the company's focus on Ayurvedic & Herbal and Advanced Oncology categories. Demonstrating compliance with FDA regulations, including cGMP standards and appropriate certifications, will be crucial. Identifying gaps in Xxosixxlarxxnewxx Lixxted's current sourcing, such as unmet demand for specific formulations or therapeutic areas, can provide avenues for new suppliers to enter the market.

2Requirements & Qualifications

Indian exporters seeking to supply Xxosixxlarxxnewxx Lixxted and the broader U.S. market must ensure their products meet FDA standards, including obtaining necessary approvals and certifications. Compliance with cGMP regulations, as recognized by the FDA, is essential. Additionally, products must adhere to FDA labeling requirements, including language and serialization mandates. Establishing a robust quality management system and maintaining consistent product quality will enhance the attractiveness of Indian exporters to U.S. importers.

3How to Approach

Frequently Asked Questions — Xxosixxlarxxnewxx Lixxted

What products does Xxosixxlarxxnewxx Lixxted import from India?

Xxosixxlarxxnewxx Lixxted imports 2 pharmaceutical products across 2 categories. Top imports: Ras ($1.5M), Trastuzumab ($350.0K).

Who supplies pharmaceuticals to Xxosixxlarxxnewxx Lixxted from India?

Xxosixxlarxxnewxx Lixxted sources from 1 verified Indian suppliers. The primary supplier is Biocon Biologics India Limited (100.0% of imports, $1.7M).

What is Xxosixxlarxxnewxx Lixxted's total pharmaceutical import value?

Xxosixxlarxxnewxx Lixxted's total pharmaceutical import value from India is $1.9M, based on 37 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Xxosixxlarxxnewxx Lixxted focus on?

Xxosixxlarxxnewxx Lixxted imports across 2 categories. The largest: Ayurvedic & Herbal Products (81.1%), Advanced Oncology (18.9%).

Get Full Xxosixxlarxxnewxx Lixxted Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.